Stock Scorecard



Stock Summary for Revolution Medicines Inc (RVMD) - $206.97 as of 8/11/2026 12:19:48 PM EST

Total Score

6 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for RVMD

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for RVMD

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for RVMD

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for RVMD

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for RVMD (40 out of 100)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for RVMD

BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies 8/11/2026 1:53:00 PM
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD 8/11/2026 7:12:00 AM
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus 8/11/2026 3:12:00 AM
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia 8/10/2026 4:39:00 PM
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies 8/10/2026 1:39:00 PM
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration 8/10/2026 10:00:00 AM
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next 8/10/2026 3:41:00 AM
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD 8/9/2026 7:45:00 AM
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next 8/8/2026 7:45:00 PM
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next 8/8/2026 7:39:00 PM

Financial Details for RVMD

Company Overview

Ticker RVMD
Company Name Revolution Medicines Inc
Country N/A
Description Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 3/31/2026
Next Earnings Date N/A

Stock Price History

Last Day Price 206.97
Price 4 Years Ago 23.82
Last Day Price Updated 8/11/2026 12:19:48 PM EST
Last Day Volume 2,101,103
Average Daily Volume 2,110,941
52-Week High 194.56
52-Week Low 34.00
Last Price to 52 Week Low 508.74%

Valuation Measures

Trailing PE N/A
Industry PE 42.59
Sector PE 49.78
5-Year Average PE -24.56
Free Cash Flow Ratio 53.90
Industry Free Cash Flow Ratio 37.74
Sector Free Cash Flow Ratio 109.34
Current Ratio Most Recent Quarter 11.38
Total Cash Per Share 3.84
Book Value Per Share Most Recent Quarter 7.49
Price to Book Ratio 26.58
Industry Price to Book Ratio 6.08
Sector Price to Book Ratio 8.84
Price to Sales Ratio Twelve Trailing Months 9,035.10
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 24.40
Analyst Buy Ratings 17
Analyst Strong Buy Ratings 4

Share Statistics

Total Shares Outstanding 212,596,000
Market Capitalization 44,000,994,120
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -88.52%
Reported EPS 12 Trailing Months -7.11
Reported EPS Past Year -2.29
Reported EPS Prior Year -5.91
Net Income Twelve Trailing Months -1,371,701,000
Net Income Past Year -1,131,301,000
Net Income Prior Year -600,093,000
Quarterly Revenue Growth YOY -95.20%
5-Year Revenue Growth -100.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 815,435,000
Total Cash Past Year 383,745,000
Total Cash Prior Year 543,064,000
Net Cash Position Most Recent Quarter 815,435,000
Net Cash Position Past Year 383,745,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,631,297,000
Total Stockholder Equity Prior Year 2,265,204,000
Total Stockholder Equity Most Recent Quarter 2,606,238,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -1,071,733,000
Free Cash Flow Per Share Twelve Trailing Months -5.04
Free Cash Flow Past Year -913,731,000
Free Cash Flow Prior Year -567,744,000

Options

Put/Call Ratio 0.60
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 1.40
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 52.15

System

Modified 8/12/2026 2:57:21 AM EST